Introduction
The constitutive androstane receptor (CAR; NR1I3) contributes to the inducible expression of genes involved in xenobiotics/endobiotics disposition, including cytochrome P450 (CYP2B/2C/3A) (Maglich et al., 2002; Wei et al., 2000) , UDP glucuronosyltransferases (Sugatani et al., 2005) , transporters (Kast et al., 2002) and others (Kakizaki et al., 2003) . It has been shown that the inducers of CYP2B6 and CYP3A4 genes regulate, via hCAR in human primary hepatocytes and cell lines, the induction of CYP2B6 expression by phenobarbital and other drugs (Maglich et al., 2003; Tzameli et al., 2000; Wang et al., 2003) . Large inter-individual variability exists in hepatic levels of CYP2B6 mRNA and protein and moreover, substantial inter-individual differences with respect to expression of hCAR have been reported (Chang et al., 2003; Lamba et al., 2003) . In order to understand the underlying mechanism for the interindividual variability of hCAR expression or hCAR activity, genetic variations in hCAR gene have been screened in some populations. Through genetic studies, it has been generally agreed that non-synonymous polymorphisms of hCAR gene are very rare (Lamba et al., 2005) . Meanwhile, several studies have reported the presence of alternative splicing variants (SVs) of CAR transcripts in human, mice, and rat (Choi et al., 1997) . In particular, four hCAR SVs have been repeatedly reported in human livers (Auerbach et al., 2003; Savkur et al., 2003) : an isoform with a 12-bp (4 amino acids) insertion in intron 6, an isoform with a 15-bp (5 amino acids) insertion in intron 7, an isoform with both of the insertions, and an isoform with deletion of exon 7 (39 amino acids). All of these splicing events alter the ligand binding domain of hCAR. Compared with wild-type CAR.1 protein, these SVs of hCAR had lower affinity for hCAR binding elements of target genes, decreased transactivation potential, and decreased ability to DMD #49791 8 Total RNA preparation from liver tissue was prepared using the RNase MidiKit (Qiagen, Hilden, Germany) with DNase I treatment according to supplier instructions.
RNA integrity was measured using the Agilent Bioanalyzer RNA600 Nano Lab Chip Kit (Agilent Technologies, Waldbronn, Germany). Only RNA samples with a RIN number higher than seven were used for further analyses. Each sample was reverse transcribed using 3 μ g RNA, random hexamers and the TaqMan Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Reverse transcription of RNA for subsequent analysis was carried out at 25°C for 10 min, 48°C for 90 min, and 95°C for 5 min, in order to achieve full length cDNA transcription of alternatively spliced variants.
Amplification of hCAR SVs
For amplification of exon1-and exon9-containing hCAR SVs, specific primers were designed with PRIMER 3 (http://www.genome.wi.mit.edu/cgi-bin/primer/ primer3.cgi), and their sequence homology and specificity were checked by using BLASTn (http://www.ncbi.nlm.nih.gov). To specifically amplify hCAR SVs from human livers, nested PCR was performed. Firstly, hCAR SVs were amplified using 5'-GGAGAGGCATTCCATACCAG-3' and 5'-TTCCCACTCCAGTGTATCCAG-3' primers in a total volume of 50 μl consisting of 1 μl of human liver cDNA reaction mixture, 10X PCR buffer, 1 mM MgCl 2 , 10 pmol of each primer, 0.2 mM dNTP (Invitrogen), and 2.5 U of TaKaRa LA-Taq (TaKaRa Shuzo Co., Japan). The PCR condition was 32 cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 90 s. cDNA yields of amplified SVs in some samples were low, so a second-round of nested amplification was performed using the 5'-CAGGTGACATGCTGCCTAAG-3' and 5'-This article has not been copyedited and formatted. The final version may differ from this version. TATCCAGGGTGTTCCAGGTG-3' primers and appropriate dilutions of the first-round PCR products. The conditions used were the same as the first round amplification except the number cycles being 15 instead 32 in the first PCR.
Cloning and cellular expression of hCAR SVs
The amplified hCAR SVs were separated by 6% acrylamide gel electrophoresis.
After gel staining, individual bands were excised and PCR product extracted using the Gel Extraction Kit for polyacrylamide gels (NucleoGen, Korea). More than 5 different clones containing fragments from each band were cloned into a pGEM T-Easy Vector (Promega). Highly pure plasmid was obtained by means of the Plasmid Plus Midi Kit (Qiagen), amplified and sequenced with T7 and SP6 (forward and reverse) universal primers and hCAR-specific primers. Sequencing was performed using the ABI Prism 3130XL Automated Sequencer (Applied Biosystems).
For expression of hCAR SVs, cloned hCAR fragments were transferred to expression vectors, pcDNA 3.1 (Invitrogen) and pCMV Taq2B (BD Biosciences Clontech, Palo Alto, CA, USA). The hCAR SVs in T-vector were digested with BamHI and HindIII, cloned into the expression vectors, and confirmed of its sequences using the ABI Prisim 3130XL (Applied Biosystems). Four µg of each hCAR SV expression plasmids (wild-type, SV1 to SV10) were transfected into COS-7 cells (1.0x10 5 cells/ well using 6 well plates) by Lipofectamine 2000 reagent (Invitrogen). Forty-eight hours after transfection, the cells were harvested and total protein was isolated as previously described. Twenty µg of total cellular proteins were separated by electrophoresis in a 12%
SDS-PAGE gel (Invitrogen) and transferred onto Hybond-P PVDF membrane (GE Healthcare, Piscataway, NJ, USA). The membrane was incubated with polyclonal rabbit This article has not been copyedited and formatted. The final version may differ from this version. ligands (see Figure 5 ). After transfection, cells were washed once with media and then incubated in media containing 10% charcoal/dextran treated FBS (HyClone Laboratories) with PB (0.25 mM, 0.5 mM, or 1 mM) and CITCO (1 μM, 5 μM, or 10 μM), PHY (5 μM, 25 μM or 50 μM), DEHP (1 μM, 5 μM, or 10 μM) or 0.1% DMSO (as a control) for 24 hours. Subsequently, luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega).
Quantitation of hCAR SVs mRNA in human livers
Quantification of hCAR variants mRNA was performed by specific quantitative real-time RT-PCR assays on an ABI PRISM 7900HT system (Applied Biosystems) as described previously (Jinno et al., 2004) . The specific primers were designed for the detection of either the insertion or deletion of introns and exons as following; a forward primer for hCAR WT, SV2, and SV4 was designed to span the exon 6/exon7 junction site; a forward primer for SV9 and SV10 was designed to span the exon 6/8 junction site and the intron6/exon7 junction site, respectively; a reverse primer for WT was designed to span the exon7/exon8 junction site; a reverse primer for SV2 and SV4 was designed to span the intron7/exon8 junction site; a reverse primer for SV9 was designed to span the exon8/exon9 junction site; a reverse primer for SV10 was designed to span the intron7/exon8 junction site. The different hCAR splicing variants (or splicing events) discriminated by these sets of primers, as well as the primer sequences, are depicted in Figure 1 and 
Immunoblot analysis
Liver homogenates were centrifuged at 600xg for 10 min at 4°C to precipitate the nuclear fraction. The supernatant was the cytosolic fraction. The protein concentrations of the nuclear fraction were quantitated using Bio-Rad protein assay solution (BioRad, Hercules, CA, USA). Thirty micrograms of nuclear proteins were separated on a 12%
SDS-polyacrylamide gel (Invitrogen) and transferred to a PVDF membrane (GE Healthcare). The membrane was treated with rabbit anti-human CAR (1:200, Santa
Cruz Biotechnology) and peroxidase-conjugated anti-rabbit goat IgG (1:4000, Santa
Cruz Biotechnology). For CYP2B6, the membrane was treated with goat anti-CYP2B6
(1:500, SantaCruz Biotechnology) and peroxidase-conjugated anti-goat mouse IgG
(1:4000, SantaCuz Biotechnology). Chemiluminescence was determined using the Western blotting detection reagent, ECL-Plus (GE Healthcare). The protein bandimages were read with a LAS 3000 imaging system and analyzed with Multi Gauge V 2.1 software (Fuji Film). 
Statistical analysis

Results
Eighteen hCAR SVs including four novel SVs were identified in human liver cDNA
To identify novel SVs of hCAR, we amplified hCAR cDNA using primer pairs specific for exon 1 and exon 9. RT-PCR was performed with the total RNA extract of individual human liver samples and the PCR products were analyzed by acrylamide gel electrophoresis ( Several hCAR SVs were unlikely to encode functional proteins because they had premature termination codons. SV6, with an exon 2 deletion, is out of the normal reading frame and introduced a premature termination codon. SV9, SV11, SV13, and SV15, derived from the use of the cryptic splice site in exon 2, have a deletion 67 bp from exon 2. SV10 has exon 2 and exon 4 deletions and also introduces a premature termination codon. In addition, SV13-18 had a deletion of part of the DBD, part of the hinge region, and a total or partial deletion of the LBD region. According to Lamba et al. Figure 2 . Different LBD structures may cause multiple effects from different CAR-ligands on ligand-dependent transactivation activity of SVs. In order to confirm this hypothesis, we tested the ligand-dependent transactivation of two additional CAR ligands, CITCO (1 μM, 5 μM, or 10 μM) and PHY (5 μM , 25 μM , or 50 μM ), as well as PB (0.25 mM, 0.5 mM, or 1 mM). We also tested DEHP (1 μM, 5 μM, or 10 μM) because it is known to activate certain SV form of CAR (DeKeyser et al., 2011) . Since SV9 is devoid of exon 7 in the middle of the LBD and has a pretermination codon, it was used as the negative control. As shown in 
Expression profile of hCAR SVs shows inter-individual variation and inter-ethnic variation in human livers
A previous study has identified several hCAR SVs in the liver of Caucasians (Auerbach et al., 2003) , but there are no reports on the profiling of these SVs due to the technical problems in absolute quantitation of extremely diverse SVs in human livers.
Instead, Jinno et al. (2004) reported the variability of splicing events in intron 6 and intron 7 of the hCAR gene in Caucasian liver because the SVs with splicing events in these regions are thought to contribute to the production of major splicing variants.
Similar splicing events were also found in major SVs (SV1-SV10) of the Korean cohort.
The ability to measure the splicing events of these introns might elucidate the frequency of major SVs such as SV2, SV4 (or SV7), SV5 (or WT or SV8), SV9, and SV10. To determine this, we designed specific primers to detect the partial or total retention of intron 6 and intron 7 (see Figure 1) , to detect the relative amount of each SV in 30
Korean livers and 20 Caucasian livers. Specificity of the primer pairs for each splice variant was tested by using SV clones as a template (data not shown). First, we measured the total amount of hCAR transcript using exon 1, exon 5, and exon 9 specific primer sets, which are commonly present in all SVs. (Figure 6 ). These wide variations were similarly observed when primer sets for exon 1, exon 5, and exon 9 were used (data not shown).
Next, we measured the relative amount of each SV among total hCAR transcripts in 
Protein expression of hCAR shows inter-individual variation in human livers
Immunoblot analyses were conducted using the nuclear fractions of human liver samples to study whether various hCAR SVs were detectable as stable protein isoforms.
The polyclonal antibodies recognizing the N-terminal regions shared by all the hCAR protein isoforms were employed. There can be seen two or three distinct immunoreactive bands in the nuclear fractions of the human liver homogenates ( Figure   8 ). The upper band, 40 kDa, was corresponding to the estimated size of the wild-type hCAR, and the broad band in the range of 32 to 35 kDa could be attributed to hCARSVs. Interestingly, in spite of heterogeneous hCAR transcripts, only three protein isoforms were found in western blot analysis. The expression of different hCAR isoforms showed dramatic inter-individual variation in their amounts and relative ratios.
For example, while relative expression of hCAR WT was predominant in HL 8, HL10, HL13, and HL22, other samples including HL9 showed darker lower bands which mean large amounts of hCAR SVs.
Since CYP2B6 expression is regulated by CAR, the correlation between CYP2B6
and CAR expression was investigated. The CYP2B6 expression shows also wide interindividual variation. However, between CYP2B6 and CAR WT expression and between CYP2B6 and total CAR expression, there were no statistically significant correlation ( Figure 8B and 8C ).
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
Analysis of the human genome has revealed that up to 60% of genes express multiple mRNA isoforms via alternative promoter usage or alternative splicing events, suggesting that it is one of the most significant components contributing to the functional diversity of proteins (Modrek et al., 2001 ). In the present study, we identified, Among 18 hCAR SVs, 12 had deletion of exon 2, 11 had deletion of exon 9, 2 had insertion of both introns 6 and 7, and 6 had insertion of intron 7 in combination with other splicing events (Figure 3 ). Deletion of exon 2 and exon 9 and insertion of total intron 6 produce truncated proteins at C-terminus (e.g. hCAR SV1, SV3, SV6, and SV10). These proteins are expected to be non-functional because they have no  helices H10/11 and H12 of the LBD, a key structure for interaction with coactivators and corepressors. H12 encodes the ligand-dependent activation domain, which is essential This article has not been copyedited and formatted. The final version may differ from this version. for ligand-dependent transcriptional activation of nuclear receptors in general and also for the constitutive transactivation activity of hCAR (Dussault et al., 2002; Lamba et al., 2004 ).
In the present study, we identified for the first time SVs with retention of total intron 7. The SVs with this splicing event are SV1, SV2, SV3, and SV6. Among them, SV1 and SV3 produce truncated proteins due to the retention of total intron 6. SV6 also generates a very short truncated protein due to the deletion of exon 2. These three SVs were non-functional in transactivation assay as anticipated (Figure 4 ). The proteins of SV1 and SV3 were detected in the transfected cells, but they have no transactivation activity. SV6 protein was not detected in western blot of the transfected cells. This may be due to the decreased protein stability of SV6 caused by premature termination. But SV2, with retention of intron 7, showed increased transactivation activity. The SV2 transactivated the CYP2B6 reporter gene approximately two times higher than WT. The SV2 also has a premature termination codon in the middle of intron 7 inserted.
Therefore, it does not contain the whole intact LBD structure that spans exon 4 to exon 9. In spite of the premature termination in LBD, SV2 showed higher responses to PB than any other SVs and WT. The reason for this increase may be due to the structural changes caused by the insertion of new amino acids encoded into the intron 7 sequence so that SV2 may bind hCAR ligands more strongly or may translocate the into nucleus more effectively in a ligand-dependent manner. Besides WT and SV2, SV4 and SV5 independent or ligand-dependent transactivation activity. Also, partial deletion of exon 9 in SV5 also did not significantly change transactivation activity. These results suggest that, for transactiviation activity of hCAR, an intact DBD is critical and a considerable part of LBD encoded by exon 4 to exon 7 is necessary.
Next we investigated the inter-individual variation of hCAR transcripts in human livers, including the relative expression of each SV. First, we measured total hCAR transcript using primers specific for the amplification of common regions in all major SVs (exon 1, exon 5, and exon 9). The extent of inter-individual variation was about 70-fold. Chang et al. (2003) also reported very wide inter-individual variation in hCAR mRNA expression, where a 240-fold difference was observed. Now, it seems apparent that expressional variation of hCAR mRNA is very large and this variation may lead to functional variation in human livers. However, the profiling of hCAR SVs has been very limited due to technical problems. For example, it is impossible to quantitatively measure all of hCAR SVs at the same time in the same sample. Instead, specific primers were designed to detect abnormal junctions found in SVs as in Fig. 1 . Using these sets of primers, we can distinguish five different forms of splicing variants; WT, SV2, SV4, SV9, and SV10. But due to various combinations of alternative splicing events found in other regions, except intron 6 and intron 7, WT cannot be distinguished from SV5 or SV8. Similarly, SV4 also cannot be distinguished from SV7 by our method. In spite of intrinsic technical problems, the relative quantities of non-functional SV9, SV10 and highly functional SV2 could be determined in both Korean livers and Caucasian livers. SVs are indicated as black box. The structure of each SV is described in Figure 3 . 
